AHA 2024 - According to Chisato Izumi, edoxaban was equally or more effective than warfarin for preventing thromboembolic events in patients after bioprosthetic valve surgery in the ENBALV trial.
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
AHA 2024 - According to Chisato Izumi, edoxaban was equally or more effective than warfarin for preventing thromboembolic events in patients after bioprosthetic valve surgery in the ENBALV trial.
This video was recorded during the AHA Scientific Sessions 2024 in Chicago, IL, US.
Chisato Izumi, MD, PhD is director of the heart failure department at the National Cerebral & Cardiovascular Center in Suita, Japan.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 18 November 2024
AHA 2024 - According to Chisato Izumi, edoxaban was equally or more effective than warfarin for preventing thromboembolic events in patients after bioprosthetic valve surgery in the ENBALV trial.
This video was recorded during the AHA Scientific Sessions 2024 in Chicago, IL, US.
Chisato Izumi, MD, PhD is director of the heart failure department at the National Cerebral & Cardiovascular Center in Suita, Japan.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 18 November 2024
Stay current with the best on medical education
